Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06FDR
|
|||
| Former ID |
DAP000702
|
|||
| Drug Name |
Didanosine
|
|||
| Synonyms |
didanosine; 69655-05-6; DIDEOXYINOSINE; Videx; Videx EC; Inosine, 2',3'-dideoxy-; ddIno; Didanosina; Didanosinum; DDI; BMY-40900; UNII-K3GDH6OH08; K3GDH6OH08; Didanosinum [INN-Latin]; Didanosina [INN-Spanish]; CHEBI:490877; 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine; NSC 612049; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE; NCGC00159514-02; NCGC00090691-03; DRG-0016; BMY 40900; DSSTox_CID_2927
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Approved | [1], [2] | |
| Therapeutic Class |
Anti-HIV Agents
|
|||
| Company |
Bristol-Myers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C10H12N4O3
|
|||
| Canonical SMILES |
C1CC(OC1CO)N2C=NC3=C2N=CNC3=O
|
|||
| InChI |
1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1
|
|||
| InChIKey |
BXZVVICBKDXVGW-NKWVEPMBSA-N
|
|||
| CAS Number |
CAS 69655-05-6
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9168, 595889, 596438, 596681, 597344, 601538, 602978, 622273, 833736, 7847362, 7885163, 7979070, 7979071, 12014245, 14847321, 15121787, 15121788, 15196316, 17389541, 22431600, 25819905, 26719672, 26754510, 26757698, 29215491, 34715128, 46386730, 46506255, 46508438, 48415887, 48422196, 48422428, 48423223, 48424479, 49681777, 49718183, 56463354, 57313303, 58717761, 77794640, 81093234, 87351572, 87559876, 90451743, 91612512, 92308421, 92308956, 92711314, 92729668, 103529091
|
|||
| ChEBI ID |
CHEBI:490877
|
|||
| ADReCS Drug ID | BADD_D00661 | |||
| SuperDrug ATC ID |
J05AF02
|
|||
| SuperDrug CAS ID |
cas=069655056
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Reverse transcriptase (HIV RT) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4833). | |||
| REF 2 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. | |||
| REF 3 | The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):298-304. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.